sur Opella
Opella Study Highlights Comprehensive Benefits of Cough Treatments
In a recent study by Opella, known for Mucosolvan and Bisolvon, findings suggest that effective cough treatments enhance overall patient well-being, not just symptom relief. The research underscores the critical role pharmacists play in advising patients, as a majority of treatment decisions occur in pharmacies.
The study reveals rapid relief from the first dose, showing improvements in daily activities immediately. Social interactions improved significantly within 72 hours, enhancing patients' conversational comfort and engagement in daily life. Furthermore, sleep quality saw marked enhancement after 48 hours, with a notable decline in sleep disruptions reported by patients.
Conducted in Italy, the observational study assessed Mucosolvan and Bisolvon users over a week, highlighting the products' impact on daily effectiveness and quality of life.
R. E.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Opella